At TCT, A New Vision of the Device Industry
The biggest news at this year's TCT meeting was, as anticipated, Boston Scientific's release of its latest TAXUS drug-eluting stent trial results, which showed slightly better binary restenosis rates than Johnson & Johnson's SIRIUS trial. The TAXUS results appeared to trigger a 4.5% drop in J&J's share price, surprising given that the TAXUS results weren't a dramatic improvement, but indicative of how much the companies involved with DES have at stake.
You may also be interested in...
Recent safety issues with drug-eluting stents may have opened the door ever so slightly for cardiac surgeons and coronary artery bypass graft (CABG) surgery to stage a small but noticeable comeback in the treatment of coronary artery disease.
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
A short summary of recent market and product developments in Interventional Cardiology, Spine Surgery, and Aesthetics, including: DES Safety Panel Weighs the Evidence; Percutaneous Lubar Fusion, and New Dermal Fillers.